Macular amyloidosis. Amyloidosis
Conditions
Interventions
Intervention 1: Intervention group 1: Treatment in this project is carried out using 0.025% Fluocinolone Acetonide ointment, manufactured by the Iranian company “Tehran Chemie.” The treatment involves
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Presence of macular amyloidosis lesions between the shoulder blades, on the arms, thighs, or above the chest, appearing relatively symmetrical on both sides. Having provided informed consent to participate in the study.
Exclusion criteria
Exclusion criteria: History of any treatment aimed at removing macular amyloidosis lesions within 6 weeks prior to the start of the study Pregnancy Breastfeeding Active skin infection Systemic diseases (such as diabetes, kidney, heart, respiratory, liver diseases, or severe anemia) Bleeding disorders Connective tissue diseases Genodermatoses Smoking Alcohol consumption Drug abuse History of recurrent miscarriages No medication (including nutritional supplements) use History of allergy to tranexamic acid or fluocinolone
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pigmentation improvement. Timepoint: At the beginning of the intervention, before each therapy session, and two weeks after the last therapy session. Method of measurement: Pigmentation Scoring System.;Pigmentation pattern. Timepoint: At the beginning of the intervention, before each therapy session, and two weeks after the last therapy session. Method of measurement: Examination of the lesion’s waviness.;Pigmentation percentage. Timepoint: At the beginning of the intervention, before each therapy session, and two weeks after the last therapy session. Method of measurement: Pigmentation Percentage Scoring System.;Skin thickness. Timepoint: At the beginning of the intervention, before each therapy session, and two weeks after the last therapy session. Method of measurement: Examination for the presence of lesion lichenification.;Itching level. Timepoint: At the beginning of the intervention, before each therapy session, and two weeks after the last therapy session. Method of measurement: Visual Analog Scale.;Patient satisfaction. Timepoint: At the beginning of the intervention, before each therapy session, and two weeks after the last therapy session. Method of measurement: Patient Satisfaction Scoring System. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Nooshin Bagherani
Arak University of Medical Sciences
Outcome results
None listed